Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Tonkin

Showing results (131-140 of 163) with videos related to

Pageof 17
Sort By:
The Medical Journal of Australia|July 22, 2008
Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot studyMark R Nelson, Christopher M Reid, David A Ames, et al.
BMC Cardiovascular Disorders|January 8, 2017
Development of an Australian cardiovascular disease mortality risk score using multiple imputation and recalibration from national statisticsKathryn Backholer, Yoichiro Hirakawa, Andrew Tonkin, et al.
International Journal for Equity in Health|June 25, 2017
Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular diseaseBlake Angell, Tracey-Lea Laba, Tom Lung, et al.
Nature Aging|April 28, 2023
Trajectories of depressive symptoms in older adults and associated health outcomesBruno Agustini, Mojtaba Lotfaliany, Mohammadreza Mohebbi, et al.
Journal of the American Geriatrics Society|May 14, 2020
Patterns of Association between Depressive Symptoms and Chronic Medical Morbidities in Older AdultsBruno Agustini, Mojtaba Lotfaliany, Robyn L Woods, et al.
American Heart Journal|December 5, 2016
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)Michael A Blazing, Robert P Giugliano, James A de Lemos, et al.
Journal of the American Heart Association|October 25, 2013
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease studyHarvey D White, John Simes, Ralph A H Stewart, et al.
JACC. Advances|October 22, 2025
Genomic Risk Prediction of Incident Atrial Fibrillation in Older Individuals Without Prior Cardiovascular DiseasePeter Daniel Fransquet, Chenglong Yu, Cammie Tran, et al.
Archives of Internal Medicine|January 14, 2004
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysesCharles H Hennekens, Frank M Sacks, Andrew Tonkin, et al.
European Journal of Preventive Cardiology|March 6, 2016
Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular diseaseVanessa Selak, Chris Bullen, Sandrine Stepien, et al.
Pageof 17

Showing results (131-140 of 163) with videos related to

Sort By:
Pageof 17
The Medical Journal of Australia|July 22, 2008
Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot studyMark R Nelson, Christopher M Reid, David A Ames, et al.
BMC Cardiovascular Disorders|January 8, 2017
Development of an Australian cardiovascular disease mortality risk score using multiple imputation and recalibration from national statisticsKathryn Backholer, Yoichiro Hirakawa, Andrew Tonkin, et al.
International Journal for Equity in Health|June 25, 2017
Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular diseaseBlake Angell, Tracey-Lea Laba, Tom Lung, et al.
Nature Aging|April 28, 2023
Trajectories of depressive symptoms in older adults and associated health outcomesBruno Agustini, Mojtaba Lotfaliany, Mohammadreza Mohebbi, et al.
Journal of the American Geriatrics Society|May 14, 2020
Patterns of Association between Depressive Symptoms and Chronic Medical Morbidities in Older AdultsBruno Agustini, Mojtaba Lotfaliany, Robyn L Woods, et al.
American Heart Journal|December 5, 2016
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)Michael A Blazing, Robert P Giugliano, James A de Lemos, et al.
Journal of the American Heart Association|October 25, 2013
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease studyHarvey D White, John Simes, Ralph A H Stewart, et al.
JACC. Advances|October 22, 2025
Genomic Risk Prediction of Incident Atrial Fibrillation in Older Individuals Without Prior Cardiovascular DiseasePeter Daniel Fransquet, Chenglong Yu, Cammie Tran, et al.
Archives of Internal Medicine|January 14, 2004
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysesCharles H Hennekens, Frank M Sacks, Andrew Tonkin, et al.
European Journal of Preventive Cardiology|March 6, 2016
Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular diseaseVanessa Selak, Chris Bullen, Sandrine Stepien, et al.
Pageof 17